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Targeting EGFR exon 20 insertion mutations in non-small
cell lung cancer
Simon Vyse 1 and Paul H. Huang1
Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the ﬁrst
EGFR mutations to be identiﬁed as oncogenic drivers in non-small cell lung cancer (NSCLC). However, unlike the classical EGFR
L858R point mutation or exon 19 deletions, which represent the majority of EGFR mutations in NSCLC, low frequency EGFR exon 20
insertion mutations are associated with de novo resistance to targeted EGFR inhibitors and correlate with a poor patient prognosis.
Here, we review the developments over the last 5 years in which pre-clinical studies, including elucidation of the crystal structure of
an EGFR exon 20 insertion mutant kinase, have revealed a unique mechanism of kinase activation and steric conformation that
deﬁne the lack of response of these EGFRmutations to clinically approved EGFR inhibitors. The recent development of several novel
small molecule compounds that selectively inhibit EGFR exon 20 insertions holds promise for future therapeutic options that will be
effective for patients with this molecular subtype of NSCLC.
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INTRODUCTION
Lung cancer is the most common malignant disease and the
leading cause of cancer mortality worldwide, with non-small cell
lung cancer (NSCLC) comprising the vast majority (85%) of all lung
malignancies.1,2 Over the last decade, our understanding of NSCLC
has evolved beyond broad histological subtypes and ‘one size ﬁts
all’ treatment approaches toward a reﬁned disease classiﬁcation
underpinned by deﬁned genetic alterations and precision
therapies guided by molecular stratiﬁcation. For the adenocarci-
noma subtype of NSCLC in particular, signiﬁcant improvements in
progression-free survival (PFS) have been achieved for patients
with epidermal growth factor receptor (EGFR) mutations, anaplas-
tic lymphoma kinase (ALK) translocations, ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) rearrangements and, B-raf proto-
oncogene, serine/threonine kinase (BRAF) mutations due to the
effectiveness and availability of therapies that speciﬁcally target
these molecular drivers.3–7 Among these advances, the successful
use of EGFR inhibitors to treat EGFR mutant positive adenocarci-
noma and the subsequent development of third generation
inhibitors to tackle acquired drug resistance have become the
poster child of targeted therapy in oncology.8,9
A series of studies in the early 2000s observed that distinct
epidemiological subgroups of patients with NSCLC (correlating
with women, Asian populations and non-smokers) had dramati-
cally enhanced responses to treatment with the ATP-competitive,
reversible EGFR inhibitors geﬁtinib and erlotinib.10–12 In multiple
reports, the vast majority of geﬁtinib-responsive or erlotinib-
responsive lung cancers were found to harbor somatic EGFR
mutations, while no EGFR mutations could be detected in non-
responsive patients.13–15 These pioneering studies indicated that
the presence of EGFR mutations predicted increased sensitivity to
EGFR inhibitors, a ﬁnding that has subsequently been supported
by numerous follow-up studies. The Iressa Survival Evaluation in
Lung Cancer (ISEL) clinical trial, for example, compared
geﬁtinib treatment to placebo in NSCLC and found that the
response rate (RR) to geﬁtinib was much higher (37.5%) in patients
who possessed EGFR mutations compared to those without
(2.6%).16 Another study, the Iressa Pan-Asia Study (IPASS)
trial, compared geﬁtinib treatment to carboplatin plus paclitaxel
and showed an extraordinary 72.1% versus 1.1% RR to geﬁtinib for
patients with and without EGFR mutations, respectively, alongside
signiﬁcantly increased PFS in the geﬁtinib-treated, EGFR mutation-
positive group.17 Subsequently, the phase III European Tarceva
vs. Chemotherapy (EURTAC) trial also showed a signiﬁcant
advantage for erlotinib (64% RR, 9.7 months PFS) in EGFR
mutant patients compared to cisplatin or carboplatin plus
either docetaxel or gemcitabine chemotherapy (18% RR,
5.2 months PFS).4
The single point mutation leucine-858 to arginine (L858R) in
exon 21 and variable deletions of at least three amino acid
residues in exon 19 are together often referred to as ‘classical’
EGFR activating mutations and represent the vast majority
(85–90%) of all observed EGFR kinase domain mutations in
NSCLC.18 It is now clear, however, that not all activating EGFR
mutations are inherently sensitive to EGFR inhibitors. Inframe base
pair insertions in exon 20 also result in constitutive activation of
EGFR, but unlike the classical activating EGFR mutations, EGFR
exon 20 insertions are associated with de novo resistance to
current clinically available EGFR inhibitors.19,20 Low response rates
of between 3–8% for erlotinib, geﬁtinib and the second
generation EGFR inhibitor afatinib have been reported in EGFR
exon 20 insertion mutant NSCLC patients (Table 1),21,22 and thus,
effective treatment options are limited. In recent years, pre-clinical
work has sought to establish the reasons underlying the failure of
EGFR inhibitors in NSCLC patients harboring EGFR exon 20
insertion mutations. Several candidate inhibitors have since been
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developed that selectively target the EGFR exon 20 insertion
mutant kinase (Fig. 1). Moving forward, these novel EGFR
inhibitors are poised to provide viable therapeutic options that
could soon beneﬁt patients with this molecular subtype of NSCLC.
INCIDENCE OF EGFR EXON 20 INSERTIONS IN NSCLC
EGFR exon 20 insertion mutations are heterogeneous at the
molecular level but can be characterized as inframe insertions or
duplications of between 3 and 21 bp (corresponding to 1 to 7
Table 1. Key clinical trials in EGFR exon 20 insertion positive NSCLC
Inhibitor(s) Target(s) Clinical trial ID(s) Key results Refs
Geﬁtinib/Erlotinib EGFR Retrospective analysis of clinical
studies
<3 months PFS 8–27% RR 52,53
Dacomitinib EGFR/HER2/HER4 NCT00225121 PR for 1 patient with D770delinsGY 61
Afatinib EGFR/HER2/HER4 NCT00525148 NCT00949650
NCT01121393
8.7% RR, 2.7 months PFS 59
Neratinib EGFR/HER2/HER4 NCT00266877 0% RR 55
Osimertinib EGFR T790M NCT03414814 Ongoing 67–69
Poziotinib EGFR/HER2 NCT03066206 Ongoing, 64% RR 31
Cetuximab+ erlotinib EGFR NCT00895362 D770>GY patient with 3.5 years PFS 81
Cetuximab+ afatinib EGFR NCT03727724 Preliminary report, 3 out of 4 ex20ins patients with PR,
5.4 months PFS
82
Luminespib Hsp90 NCT01854034 17% RR, 2.9 months PFS 96
Tarloxotinib EGFR – Pre-clinical inhibition of ex20ins EGFR 89
TAK-788 EGFR/HER2 ex 20
ins
NCT02716116 Ongoing, preliminary anti-tumor activity reported 92
TAS6417 EGFR ex 20 ins – Pre-clinical inhibition of ex20ins EGFR 93
Compound 1A EGFR/HER2 ex 20
ins
– Pre-clinical inhibition of ex20ins EGFR 94
Details for trials with NCT numbers can be accessed on https://clinicaltrials.gov/
PFS progression-free survival, PR partial response, RR response rate, ex20ins exon 20 insertion
Fig. 1 Developments in understanding EGFR exon 20 insertion-positive NSCLC. A timeline of key clinical and pre-clinical studies that have
established the response of EGFR exon 20 insertion NSCLC to EGFR inhibitors and recent progress towards the development of novel
therapeutic strategies for this molecular subtype
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amino acids) clustered between amino acid positions 762 and 774
of the EGFR protein.22 The most common insertion sites in EGFR in
NSCLC are shown in Fig. 2. Exon 20 insertions were among the
earliest EGFR mutations identiﬁed in NSCLC alongside exon 19
deletions and L858R mutations.23,24 However, reports regarding
the incidence and clinical outcome of NSCLC patients with these
insertions were initially limited. The frequency of EGFR exon 20
insertions has since been reported as being between 4 and 10% of
all observed EGFR mutations in NSCLC.19,21,22,25 EGFR exon 20
insertion mutations are largely mutually exclusive with other
known oncogenic driver events that are characteristic of NSCLC,
such as KRAS mutations,26 and follow similar trends as classical
activating EGFR mutations; EGFR exon 20 insertion mutations are
enriched in women, non-smokers, Asian populations, and those
with adenocarcinoma histology.25
Until recently, EGFR exon 20 insertion mutations have been
exclusively reported in NSCLC. Interestingly, however, recent
analysis of a rare form of head and neck cancer known as
sinonasal squamous cell carcinoma (SNSCC) demonstrated a
remarkably high frequency of EGFR mutations (77% of SNSCC
tumors), the majority of which were exon 20 insertions (88% of all
EGFRmutations).27 This result is striking given that EGFRmutations
in head and neck cancer are rare overall, and moreover, the
frequency of EGFR mutations is inverse to that of NSCLC; in SNSCC
tumors, exon 20 insertion mutations predominate, while exon 19
deletions are detected at low frequency.27,28 Thus, EGFR exon 20
insertions are not entirely restricted to lung cancer as previously
believed but can also act as oncogenic drivers in SNSCC, which
represents approximately 3% of all head and neck cancers.29,30
Notably, structurally analogous exon 20 insertion mutations that
can promote ligand-independent activation that are also found in
HER2, another member of the EGFR family of receptor tyrosine
kinases (RTK).23,31 Although HER2 mutations are present at a much
lower frequency (~2% of NSCLC patients) compared with EGFR
mutations, exon 20 insertions are, by far, the most dominant type
of HER2 aberration in NSCLC, representing greater than 90% of all
observed HER2 mutations.32,33
IMPACT OF EXON 20 INSERTIONS ON EGFR STRUCTURE,
ACTIVITY, AND SENSITIVITY TO EGFR INHIBITORS
EGFR was the ﬁrst RTK to be identiﬁed and belongs to a subset of
RTKs known as the EGFR family.34,35 For wild-type EGFR, ligand
binding is required for activation and induces a conformational
change that facilitates receptor homo-dimerization or hetero-
dimerization with other EGFR family members. Subsequent
autophosphorylation of the tyrosine residues in the intracellular
tail of EGFR initiates the formation of large protein complexes that
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Fig. 2 EGFR Exon 20 insertion mutations in NSCLC. Within NSCLC, all EGFR mutations are clustered across exons 18–22 which encode the
tyrosine kinase domain. In particular, 4–10% of EGFR mutations are heterogeneous in-frame insertions of between 1–7 amino acids (indicated
as ins X) across a span of ~15 amino acids (D761–C775) in exon 20. The prevalence of exon 20 insertions that occur at different amino acid
positions are shown by the red bars. Mutations occur within the C-terminal end of the C-helix or more frequently in the loop that immediately
follows. Mutation frequency distribution was calculated using COSMIC v86 (http://cancer.sanger.ac.uk) after ﬁltering for NSCLC
adenocarcinomas harboring exon 20 insertions (n= 349)98
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can propagate downstream signaling.36–38 Many of the signaling
pathways activated downstream of EGFR, including the Ras/Raf/
Mitogen-activated protein kinase (Ras/MAPK) pathway, phospha-
tidylinositol 3-kinase/AKT (PI3K/AKT) pathway, and signal transdu-
cers and activators of transcription (STAT) pathway orchestrate key
cellular processes including cell survival, proliferation, and
migration. As such, it follows that dysregulation of EGFR has the
potential to contribute to almost all of the classical oncogenic
phenotypes that have been described as the ‘hallmarks of
cancer’.39
The conformational changes induced by the L858R mutation
and exon 19 deletions have been predicted to destabilize the
inactive form of EGFR, causing an overall equilibrium shift towards
an active over an inactive state.40–42 This shift allows ligand-
independent dimerization and activation of the receptor, resulting
in constitutive activation of downstream signaling pathways. In
lung cancers with classical EGFR mutations, blockade of EGFR
signaling with inhibitors can trigger rapid apoptosis in a manner
consistent with the ‘oncogene addiction’ model, in which cells are
dependent on persistent EGFR signaling for survival.43 Impor-
tantly, kinetic analyses have revealed that both L858R and exon 19
deletion EGFR kinases display a greatly reduced afﬁnity for ATP
relative to the wild-type receptor.44,45 Diminished ATP binding has
the opposite effect on drug binding; the relative afﬁnity of mutant
receptors for reversible ATP-competitive EGFR inhibitors, such as
geﬁtinib or erlotinib, is potently enhanced by alleviating the
competitive pressure. This differential sensitivity between wild-
type and mutant receptors, combined with the increased
dependency of tumor cells on EGFR signaling, provides the wide
therapeutic window that makes EGFR inhibitor therapy much
more effective in patients with classical activating EGFR mutations.
A second mutational event in EGFR, the T790M substitution in
exon 20, is thought to account for more than half of all cases of
acquired resistance to ﬁrst-generation EGFR inhibitors in NSCLC.46
It was initially predicted that the mechanism of resistance
underlying the T790M mutation was steric hindrance imposed
by the presence of a bulky methionine residue that would prevent
the binding of ﬁrst-generation EGFR inhibitors to EGFR. However,
while the T790M mutation was found to impact the afﬁnity of the
mutant EGFR receptor to geﬁtinib, inhibitor binding was not
completely abolished.47 Crucially, further analysis revealed
another major factor that contributed to drug resistance: the
T790M mutation restored the ATP-binding afﬁnity of the L858R
mutant EGFR to almost wild-type receptor levels.40,47 By increasing
the ATP afﬁnity, the T790M mutation diminishes the efﬁcacy of
reversible ATP-competitive inhibitors geﬁtinib and erlotinib, and
removes the selectivity that these drugs have for mutant over
wild-type EGFR.
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Fig. 3 Impact of deletions and insertions on EGFR activation. Upon ligand-binding, the regulatory C-helix pivots from an outward, inactive
conformation to an inward, active conformation to form key interactions with the p-loop of the active site located in the cleft between the
N-lobe and C-lobe. Oncogenic mutations such as exon 19 deletions can “pull” the C-helix from the N-terminal side whilst exon 20 insertions
“push” from the C-terminal side to stabilize the active state of EGFR even in the absence of ligand
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Similarly, the unique mechanism of EGFR activation induced by
exon 20 insertions underlies the relative resistance of these
mutations to clinically approved EGFR inhibitors. Exon 20
insertions are positioned towards the C-terminal end of a speciﬁc
structural component of EGFR known as the C-helix. The C-helix is
a key regulatory element that dictates the activation status of
EGFR by rotating from an outward to an inward position,
permitting speciﬁc interactions with the active site that stabilize
dimerization-competent EGFR.40 Exon 19 deletions in EGFR affect
this region via removal of residues from the loop that leads up to
the C-helix on the N-terminal side (Fig. 3). The shortening of this
loop as a result of exon 19 deletions has been hypothesized to
“pull” and restrict the rotation of the C-helix, preventing it from
adopting the outward, inactive conformation and favoring the
inward, active conformation. It is by this mechanism that exon 19
deletion mutations have been predicted to exert the equilibrium
shift towards active over inactive EGFR states, promoting
constitutive receptor activation. Conversely, exon 20 insertions
at the opposite C-terminal end of the C-helix, or much more
commonly in the loop that immediately follows it, have been
predicted to “push” the C-helix into an active conformation from
the other direction.40
In 2013, Yasuda et al. solved the ﬁrst crystal structure of a
representative exon 20 insertion EGFR mutation, D770_N771insNPG,
which provided valuable insights into the mechanism of EGFR
activation and drug resistance associated with exon 20 insertion
mutations.22 The crystal structure of D770_N771insNPG revealed an
active conformation with the C-helix adopting an inward position.
The position of the insertion formed a wedge at the “pivot point” of
the C-helix, creating a rigid, inﬂexible structure that likely prevents
the reorientation of the C-helix to the outward, inactive state,
conﬁrming previous predictions. In this manner, exon 20 insertions
essentially “lock” EGFR molecules in an active conformation in the
absence of ligand binding. Further analysis of the crystal structure
together with in vitro kinetic studies performed on puriﬁed kinase
domains provided an explanation for the insensitivity of exon 20
insertion mutations to EGFR inhibitors. Yasuda et al. observed that
the D770_N771insNPG mutation is capable of activating EGFR
without markedly diminishing ATP afﬁnity or enhancing afﬁnity for
the ﬁrst-generation inhibitor geﬁtinib.22 Thus, the two key features
that confer the exquisite sensitivity of L858R and exon 19 deletion
EGFR mutations to ﬁrst-generation EGFR inhibitors are absent in the
presence of exon 20 insertions, and the therapeutic window to
target mutant over wild-type EGFR is lost. A later study used
computational modeling of the solved D770_N771insNPG crystal
structure to attribute the lack of afﬁnity for ﬁrst-generation EGFR
inhibitors to a prominent shift of the C-helix and phosphate-binding
loop (p-loop) of EGFR into the drug-binding pocket, resulting in
signiﬁcant steric hindrance.31
It is important to note that EGFR exon 20 insertion mutations are
heterogeneous and that the location of the insertion, in particular,
may inﬂuence the kinetics of drug and ATP binding, ultimately
determining resistance or sensitivity to EGFR inhibitors. Indeed,
Yasuda et al. also investigated another exon 20 insertion that
occurred within the C-helix of EGFR, A763_Y764insFQEA, and
unexpectedly found that this mutation had a high afﬁnity for
geﬁtinib in vitro and was highly sensitive to erlotinib in an
engineered cell line model.22 Three patients with the
A763_Y764insFQEA insertion showed tumor regression or stable
disease following erlotinib treatment, leading the authors to
conclude that unlike other mutations of its class, this particular
exon 20 insertion is sensitive to ﬁrst-generation EGFR inhibitors.
Although its crystal structure was not solved, 3D modeling of the
A763_Y764insFQEA insertion suggests that exon 20 insertions that
occur before residue 764, within the C-helix itself, might have an
activation mechanism and structure that more closely resemble
those of the L858R or exon 19 deletion mutant EGFR and therefore
would be predicted to be sensitive to ﬁrst-generation EGFR
inhibitors. In agreement, multiple reports have shown partial
responses of patients harboring A763_Y764insFQEA insertions to
the ﬁrst-generation inhibitor erlotinib, indicating that these
mutations may behave similarly to classical NSCLC EGFR muta-
tions.19,48 An outstanding question is whether the downstream
signaling pathways activated by distinct EGFR exon 20 insertion
mutations are the same and to what degree these pathways
overlap with those activated by the more common L858R or exon
19 deletion EGFRmutations. Previous work has shown that distinct
EGFR mutations drive unique downstream signaling proﬁles.49–51
Future characterization of the downstream pathway activation
that is unique to EGFR exon 20 insertions may yield mutation-
speciﬁc therapies that selectively target these pathways.
TREATMENT OPTIONS FOR EGFR EXON 20 INSERTION NSCLC
First-generation EGFR inhibitors
Commonly referred to as the ‘ﬁrst-generation’ EGFR inhibitors,
geﬁtinib and erlotinib are reversible, ATP-competitive inhibitors
that selectively target exon 19 deletion and L858R mutant EGFR
over wild-type and have been the gold standard of EGFR-mutant
positive NSCLC treatment, achieving up to a 72% RR and nearly
10 months PFS.4,16,17 By contrast, with the exception of the
A763_Y764insFQEA mutation,19,48 retrospective analysis of clinical
data has revealed that ﬁrst-generation EGFR inhibitors are
ineffective in the vast majority of EGFR exon 20 insertion mutant
NSCLC patients, with a RR between 8 and 27% and less than
3 months median PFS reported (Table 1).52,53
Second-generation EGFR inhibitors
Three second-generation EGFR inhibitors have been developed:
neratinib, dacomitinib, and afatinib. Unlike the ﬁrst-generation
drugs geﬁtinib or erlotinib, all of these compounds form
irreversible, covalent interactions with EGFR at a speciﬁc cysteine
residue (C797) and have additional activity against at least one
other EGFR family member.54 A phase II clinical trial
(NCT00266877) of neratinib reported a low RR of only 3% in
classical EGFR mutant positive lung adenocarcinoma tumors, and
there are currently no ongoing clinical trials to assess neratinib in
lung cancer.55 An ongoing phase III clinical trial, ARCHER 1050
(NCT01774721), has recently demonstrated signiﬁcantly longer
median PFS after dacomitinib treatment (14.7 months) versus
geﬁtinib treatment (9.2 months) in NSCLC patients harboring
classical EGFR mutations, leading to FDA approval for dacomitinib
to treat metastatic EGFR mutant-positive NSCLC in September
2018.56 Afatinib is also approved as a ﬁrst-line therapy for the
treatment of NSCLC harboring classical EGFR mutations based on
two pivotal studies that demonstrated a signiﬁcant PFS beneﬁt of
greater than 10 months in EGFR-mutant patients.57,58
Currently, there is limited clinical evidence that supports the use
of second-generation EGFR inhibitors in exon 20 insertion mutant
NSCLC. A recent post-hoc analysis of data from 100 lung cancer
patients harboring rare EGFR mutations pooled from LUX-Lung 2,
LUX-Lung 3, and LUX-Lung 6 trials revealed signiﬁcant clinical
activity of afatinib (71.1% RR, 10.7 months PFS) in rare EGFR point
mutations (G719X, S786I, L861Q).59 This ﬁnding led the FDA to
broaden the indication for afatinib to include NSCLC patients who
harbor these speciﬁc mutations in January 2018. However, in the
same analysis, a group of 23 patients harboring EGFR exon 20
insertions treated with afatinib were found to have a minimal
response (8.7% RR, 2.7 months PFS).
Interestingly, a comprehensive pre-clinical study of exon 20
insertions in EGFR and HER2 in engineered Ba/F3 and NIH-3T3 cell
line models has identiﬁed a variable degree of responses to the
second-generation inhibitors dacomitinib, neratinib, and afatinib
across distinct exon 20 insertions.60 In particular, the authors
noted that insertions that introduced a glycine at position 770
were uniquely sensitive to the EGFR/HER2 inhibitor dacomitinib,
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suggesting a potential therapeutic avenue for patients with
mutations that share this feature. In a 2011 phase I clinical trial,
out of 6 patients with different EGFR exon 20 insertion mutations,
the only patient who demonstrated a partial response to
dacomitinib harbored a D770delinsGY mutation, supporting the
pre-clinical data.61 However, these mutations are relatively rare—
the most common exon 20 insertions lack glycine at position 770;
therefore, the majority of patients within this NSCLC molecular
subgroup are unlikely to beneﬁt from dacomitinib treatment.
Consistent with the clinical data, the pre-clinical study found that
only the cell line models expressing a D770delinsGY mutation
possessed an in vitro IC50 that was sufﬁciently low enough
(17.5 nM) to predict a response to dacomitinib in patients based
on current dosing regimens (a 45 mg once per day dose, which is
an approximately 120–160 nmol/L trough concentration).62
Third-generation EGFR inhibitors
In response to the identiﬁcation of the T790M secondary mutation
as a major source of resistance to ﬁrst-generation EGFR inhibitors
in NSCLC, third-generation EGFR inhibitors that covalently bind to
the C797 cysteine residue of EGFR and maintain selectivity for the
double mutant L858R/T790M or exon 19 del/T790M EGFR have
been developed.46,63,64 Two major T790M-selective irreversible
EGFR inhibitors, rociletinib, and osimertinib, have been assessed in
the context of EGFR T790M-mutant positive NSCLC, and based on
its impressive response rate of greater than 60%, the FDA granted
approval for osimertinib as a second-line treatment for EGFR
T790M mutant-positive patients following progression on erlotinib
or geﬁtinib in 2017.8,9,65 Recently, osimertinib has also demon-
strated a signiﬁcant beneﬁt versus ﬁrst-generation EGFR inhibitors
in previously untreated NSCLC patients harboring classical EGFR
mutations. In 556 EGFR-mutant patients, osimertinib-treated
patients reached an unprecedented median PFS of 17.2 months
versus 8.5 months with ﬁrst-generation EGFR inhibitor treatment,
leading to its recent approval as a ﬁrst-line therapy.66
Pre-clinical in vitro evidence in engineered cell line models has
suggested that osimertinib may have some activity against EGFR
exon 20 insertions, albeit with a weaker potency than afatinib.31,67
However, the evidence to support osimertinib as a candidate
inhibitor for EGFR exon 20 insertions in vivo remains unclear. A
study of lung cancer patient-derived xenograft (PDX) models
harboring EGFR exon 20 insertion mutations showed poor
responses to the third-generation EGFR inhibitors osimertinib
and rociletinib.68 However, Floc’h et al. have recently demon-
strated signiﬁcant antitumor activity of both osimertinib and its
circulating metabolite AZ5104 using xenograft models of the
H2073 EGFR wild-type lung cancer cell line, which was genetically
engineered to introduce either the D770_N771InsSVD or
V769_D770InsASV EGFR insertion mutations.69 A phase II clinical
trial to assess osimertinib as a treatment for EGFR exon 20
insertion mutant NSCLC (NCT03414814) is ongoing.
Poziotinib
Poziotinib (formerly HM781–36B) is a covalent, irreversible
inhibitor of EGFR and HER270 that is currently the most advanced
clinical candidate of compounds with the capacity to target EGFR
exon 20 insertions. Initially, a phase II study of poziotinib in NSCLC
patients with classical EGFR mutations who had acquired
resistance to EGFR inhibitors via the T790M mutation or other
mechanisms found that poziotinib had minimal clinical activity.71
Poziotinib was subsequently shown to have signiﬁcant activity
against EGFR exon 20 insertions in in vitro models, a result which
was mirrored by encouraging clinical data from an ongoing phase
II trial (NCT03066206).31 Robichaux et al. used 3D modeling to
demonstrate how the rigid C-helix conformation induced by exon
20 insertions results in a relatively small drug binding pocket. This
restricted conformation has been predicted to prevent the
binding of drugs such as osimertinib, which has a large terminal
group and a rigid pyrimidine core, by steric hindrance. By contrast,
poziotinib is centered on a less rigid quinazoline core, akin to
second-generation EGFR inhibitors. In addition, poziotinib has
small terminal and substituent linking groups, making it more
compact and ﬂexible compared to current second-generation and
third-generation inhibitors. Based on these features, 3D modeling
predicts that poziotinib is able to tightly bind the restricted exon
20 insertion binding pocket of EGFR and may also be effective
against structurally analogous exon 20 insertions in HER2.
Following these structural modeling studies, the authors
demonstrated potent inhibition of exon 20 insertion EGFR and
HER2 mutants in a series of engineered Ba/F3 cell line models. In
these cell lines, poziotinib was shown to be uniquely selective for
exon 20 insertions over T790M mutants, providing a possible
explanation for the initial disappointing results in patients with
acquired resistance to EGFR inhibitors in the phase II trial.71
However, it is important to note that poziotinib also demonstrated
activity against wild-type EGFR in vitro, highlighting a possible
narrow therapeutic window that may give rise to dose limitations
in EGFR exon 20 insertion patients. Using genetically engineered
mouse models harboring EGFR D770insNPG or HER2 A775insYVMA
lung tumors, a durable response to poziotinib was shown over
12 weeks of treatment in vivo. Additionally, poziotinib was
compared to afatinib in a mouse xenograft model of a patient-
derived cell line, YUL-0019, which harbors EGFR N771delinsFH.
Although YUL-0019 tumors did not grow in the presence of
afatinib, tumor volume remained stable over the course of
10 days. By contrast, poziotinib treatment resulted in a 50%
reduction of tumor volume within the same time frame.
The authors also reported preliminary data from an ongoing
phase II clinical trial for poziotinib in EGFR exon 20 insertion-
positive lung cancer patients (NCT03066206). Although the
patient cohort was small, a striking 64% conﬁrmed response rate
was achieved in 11 patients harboring EGFR exon 20 insertion
mutations. This promising result is in stark contrast to the 8.7%
response rate that has previously been observed for afatinib in
exon 20 insertion patients.59 It is important to note, however, that
the clinical data from this trial are not mature and the median PFS
and OS have not yet been reported. Therefore, a question remains:
how durable will the response to poziotinib be in patients with
exon 20 EGFR insertions? Anticipating the emergence of acquired
resistance, Robichaux et al. indirectly showed a possible mechan-
ism that parallels osimertinib resistance by demonstrating that Ba/
F3 cells expressing EGFR L858R/T790M/C797S or EGFR exon 19
deletion/T790M/C797S triple mutants are resistant to poziotinib
treatment in vitro. The C797S EGFRmutation has been found to be
a major clinical mechanism of acquired resistance to osimertinib
treatment in patients with classical EGFR mutants who are
concurrently T790M positive.72 However, whether the C797S
mutation arises in patients with exon 20 insertion mutations has
yet to be determined. Similarly, whether poziotinib is clinically
effective across a broad spectrum of different EGFR exon 20
insertions with sufﬁcient selectivity over wild-type EGFR to achieve
target inhibition with minimal toxicity remains unknown. Based on
preliminary results from a phase II clinical trial including data from
a small cohort of 30 patients, poziotinib was recently declined
Breakthrough Designation Therapy status by the FDA,73 although
the trial remains ongoing to assess poziotinib in a larger cohort of
NSCLC patients harboring EGFR or HER2 exon 20 insertions
(NCT03318939).
Luminespib
Luminespib is an inhibitor of heat shock protein 90 (Hsp90), a
molecular chaperone required to maintain stability and assist
protein folding for a large number of cellular client proteins,
including receptors and signaling components involved in driving
oncogenesis.74 Importantly, Hsp90 inhibitors have shown anti-
tumor properties and selectivity for cancer cells over normal
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cells,75 and although no Hsp90 inhibitors have been approved to
date, their potential is being actively explored across many cancer
types for which treatment options are limited.76 Recently, pre-
clinical data have shown that the EGFR exon 20 insertion mutant
kinase associates with the Hsp90 chaperone system and can be
degraded through the use of Hsp90 inhibitors.77 A phase II clinical
trial of luminespib in EGFR exon 20 insertion NSCLC
(NCT01854034) reported that 5 out of 29 (17%) patients achieved
partial or complete responses, indicating an improvement over
the current RRs to ﬁrst-generation or second-generation EGFR
inhibitors.78 However, both the median PFS (2.9 months) and
overall survival (13 months) were short, while the ocular toxicity of
this class of drugs remains a concern. Therefore, it is unclear at this
stage whether luminespib will have clinical utility in EGFR exon 20
insertion NSCLC patients.
Cetuximab and EGFR inhibitor combinations
Based on in silico structural modeling, two EGFR exon 20
insertions, D770_P772del_insKG and D770>GY, were predicted
to increase the electrostatic energy between EGFR monomers and
therefore favor the formation of EGFR active dimers.79 This ﬁnding
led the authors to hypothesize that patients harboring these
insertions may be sensitive to a combination of EGFR kinase
inhibitors and cetuximab, a monoclonal antibody that binds to the
extracellular domain of EGFR and sterically hinders dimer
formation.80 Case studies from two patients support the use of
cetuximab in combination with EGFR inhibitors or chemotherapy,
including one patient (D770>GY) treated with a combination of
cetuximab and erlotinib in a phase I clinical trial with a reported
PFS of 3.5 years.79,81 More recently, a clinical study found that
three out of four EGFR exon 20 insertion-positive NSCLC patients
had partial responses to a combination of afatinib and cetuximab,
with a median PFS of 5.4 months.82 These results suggest that the
cetuximab and EGFR inhibitor combination may have some
efﬁcacy in patients with exon 20 insertions; however, with limited
clinical data, further work is necessary to determine the impact of
the insertion size and location on the response to cetuximab
combinations.
Tarloxotinib
Tarloxotinib is a hypoxia-activated prodrug (HAP) that releases an
irreversible EGFR/HER2 inhibitor only under low oxygen condi-
tions.83,84 Hypoxia is a common feature of solid tumors and, in
particular, has been linked to EGFR inhibitor resistance in pre-
clinical models.85–87 A phase II clinical trial of tarloxotinib in EGFR
mutant, T790M-negative NSCLC patients with progression on ﬁrst-
line EGFR inhibitors reported disappointing results; while 7 of 21
patients achieved stable disease, no conﬁrmed partial responses
were reported, leading to early termination of the trial.84,88
However, a recent in vivo study using murine xenografts of two
NSCLC cell lines harboring endogenous EGFR exon 20 insertions,
CUTO14 (A767_V769dupASV) and CUTO17 (N771_H773dupNPH),
has revealed signiﬁcant tumor regression with tarloxotinib
treatment compared with the lack of a tumor response to
afatinib.89 These preliminary data suggest that more focused
clinical trials are warranted to determine the efﬁcacy of
tarloxotinib within the EGFR exon 20 insertion NSCLC patient
subgroup.
EGFR EXON 20 INSERTION SELECTIVE INHIBITORS
The development of compounds with selectivity for EGFR exon 20
insertion mutants over wild-type EGFR is crucial to limit the
toxicity that arises from wild-type EGFR inhibition in patients.90
Several novel inhibitor compounds have recently been developed
and have been shown to directly target the EGFR exon 20
insertion mutant kinase. Although these developments remain at
an early stage, published data suggest that these compounds may
have signiﬁcant clinical activity in NSCLC patients harboring exon
20 insertion mutations in EGFR and HER2. In this section, we will
discuss the latest pre-clinical evidence that supports the evalua-
tion of these EGFR exon 20 insertion selective inhibitors in lung
cancer patients.
TAK-788
TAK-788 (formerly AP32788) is a covalent, irreversible inhibitor
that is designed to selectively target the exon 20 insertion mutant
forms of both EGFR and HER2 kinases over wild-type EGFR.91
Gonzalvez et al. reported selective activity of TAK-788 against 14
different EGFR exon 20 insertion mutant variants expressed in the
Ba/F3 cell line model. In the same study, tumor regression was
observed in a patient-derived xenograft NSCLC model harboring
an EGFR exon 20 insertion mutation following once daily dosing of
TAK-788. A phase I/II clinical trial (NCT02716116) is now underway
to evaluate the use of TAK-788 in NSCLC patients with exon 20
insertion mutations in EGFR or HER2. A preliminary ﬁrst report of
the dose-escalation cohort demonstrated tolerability of TAK-788 in
patients, with an adverse effect proﬁle similar to that of other
EGFR inhibitors used in NSCLC.92 Once a maximum tolerated dose
is established, the phase II expansion phase aims to determine the
overall response rate to TAK-788 in a larger cohort of NSCLC
patients harboring EGFR or HER2 exon 20 insertions either with or
without brain metastases.
TAS6417
TAS6417 (formerly TPC-064) is a newly developed irreversible
EGFR inhibitor that was designed to ﬁt into the ATP binding site of
the exon 20 insertion EGFR kinase.93 Mass spectrometry analysis
demonstrated that TAS6417 forms a covalent interaction with an
insertion mutant EGFR kinase at the cysteine residue C797. Further
pre-clinical characterization of TAS6417 by Hasako et al. demon-
strated selectivity for the D770_N771insNPG mutant EGFR kinase
over wild-type EGFR using cell-free in vitro kinase assays. To
ensure cellular activity, TAS6417 treatment was shown to inhibit
EGFR phosphorylation and cell viability in NIH3T3 cell line models
engineered to express a panel of 6 distinct EGFR exon 20 insertion
mutations. In addition, as an elegant solution to the paucity of
NSCLC cell lines harboring endogenous EGFR exon 20 insertion
mutations, the authors employed transcription activator-like
effector nuclease (TALEN) mutagenesis to generate a suitable
model derived from the H1975 EGFR L858R/T790M mutant NSCLC
cell line. TALEN mutagenesis was used to introduce an EGFR
D770_N771insSVD insertion into the H1975 cell line and subse-
quently knock out endogenous L858R and T790M mutations.
TAS6417 treatment was then shown to inhibit cell growth of the
H1975 EGFR D770_N771insSVD mutant cell line in vitro and
in vivo. It was also conﬁrmed that TAS6417 treatment resulted in
the inhibition of EGFR phosphorylation in xenografts, coupled
with evidence of inhibition of two critical pathways that mediate
oncogenic signaling downstream of EGFR, the PI3K/Akt (as
measured by pAKT) and Ras/MAPK (as measured by pERK)
pathways. Moreover, the level of EGFR signaling inhibition
correlated with the plasma concentrations of TAS6417 over a 24
h time course of treatment. Clinical assessment of TAS6417 in
NSCLC patients has not yet begun; therefore, it remains to be
determined whether the mutant selectivity of the inhibitor is
sufﬁcient to achieve a good therapeutic window with low toxicity
in EGFR exon 20 insertion-positive patients.
Compound 1A
Jang et al. have recently employed a structure-guided rational
drug design strategy to develop a currently unnamed lead
compound, referred to as ‘compound 1A’, which has activity
against EGFR and HER2 exon 20 insertion mutant kinases.94 Taking
inspiration from EGFR inhibitors that form covalent interactions
with EGFR, such as osimertinib and rociletinib,64,95 compounds
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were designed using a similar pyrimidine core structure that
had the ability to bind the cysteine residue C797 of EGFR. The
authors hypothesized that small molecule compounds that can
form additional molecular interactions with the active conforma-
tion of EGFR would have enhanced potency against the
EGFR exon 20 insertion mutant kinase. By examining the crystal
structure of wild-type EGFR complexed with osimertinib, Jang
et al. observed a deep hydrophobic pocket of EGFR positioned at
the back of the ATP-binding site that was not occupied by
osimertinib. Based on the original pyrimidine core, a novel
series of chemical compound analogues were generated by the
addition of substituents that were intended to interact with EGFR
in the deep hydrophobic pocket. In particular, the compound
identiﬁed as ‘1A’ was found to strongly inhibit EGFR phosphoryla-
tion in Ba/F3 cell lines expressing EGFR exon 20 insertion
mutations and demonstrated less potency against wild-type EGFR
compared with the second-generation EGFR inhibitors afatinib
and dacomitinib and the EGFR exon 20 targeting compound
poziotinib. Jang et al. also showed potent antiproliferative
activity against a patient-derived NSCLC cell line, DFCI127, which
harbors an EGFR P772_H773insPNP mutation. The poor pharma-
cokinetic properties of compound 1A, including its low oral
bioavailability, short half-life, and high clearance rate, remain to be
addressed before assessing the efﬁcacy of this inhibitor in in vivo
models.
CONCLUSIONS
To date, clinically approved targeted EGFR inhibitors have failed to
effectively treat NSCLC driven by EGFR exon 20 insertion
mutations.19 Crystal structures and in vitro analyses of exon 20
insertion EGFR mutant kinases have revealed that, unlike L858R or
exon 19 deletion mutant EGFR, the majority of exon 20 insertions
do not possess diminished ATP binding or enhanced afﬁnity for
ﬁrst-generation EGFR inhibitors over wild-type EGFR, thereby
reducing the therapeutic window required for their clinical
beneﬁt.22 Compounds with the ability to overcome these issues
and target EGFR exon 20 insertion mutations, therefore, present an
exciting opportunity for clinical use in this patient population. For
example, the most advanced clinical compound to date,
poziotinib, has achieved a 64% objective response rate, a
signiﬁcant improvement upon the previous 8.7% objective
response rate for afatinib59 and 17% objective response rate for
the Hsp90 inhibitor luminespib.96 Several outstanding challenges
lie ahead–for instance, given the signiﬁcant molecular hetero-
geneity of the size and location of distinct EGFR exon 20 insertions,
it will be important to determine whether all patients within this
molecular subtype of NSCLC will universally respond to these
inhibitors. Moreover, the long-term clinical durability of EGFR exon
20 insertion-selective drugs remains unclear, and identifying
eventual resistance mechanisms and strategies to overcome them
will be crucial in achieving durable patient responses. Consider-
able efforts are underway to explore the concept of synthetic
lethality to identify additional dependencies in classical mutant
EGFR-driven models that can be targeted to overcome drug
resistance.97 An unresolved question is whether EGFR exon 20
insertion-driven NSCLC will share similar downstream signaling
proﬁles and vulnerabilities that can be exploited therapeutically.
Nevertheless, based on encouraging preliminary data with EGFR
exon 20 selective compounds, it is anticipated that one or more of
these inhibitors will achieve good tolerability and clinical efﬁcacy
in patients that will lead to regulatory approval. Moving forward,
there is the exciting prospect that these selective kinase inhibitors
will provide novel and effective treatment options for patients
with EGFR exon 20 insertion mutant-positive NSCLC in the
near future.
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